2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
This guideline cites 5 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2022
- Source
- Halvorsen S, Mehilli J, et al. Eur Heart J. 2022;43(39):3826–3924.doi 10.1093/eurheartj/ehac270
The 2022 ESC guideline replaces reflexive preoperative testing with a risk-stratified pathway built on the surgical risk category, functional capacity and biomarkers, and it introduces myocardial injury after non-cardiac surgery (MINS) as a diagnosis in its own right. Much of its evidence is negative — the trials below are as important for what they stopped as for what they started.
Perioperative beta-blockade1
- 2008POISE CoreCardiology · Cardioprotection · Beta-blockadeIn 8,351 patients with or at risk of atherosclerotic disease undergoing non-cardiac surgery, extended-release metoprolol started hours before surgery reduced cardiovascular death, non-fatal myocardial infarction or non-fatal cardiac arrest at 30 days but increased death and stroke compared with placebo.HR 0.8495% CI 0.70-0.99Read →
Perioperative antithrombotic therapy3
- 2022POISE-3Cardiology · Cardioprotection · Antifibrinolytic therapyIn 9,535 patients undergoing non-cardiac surgery at risk of bleeding and cardiovascular events, intravenous tranexamic acid reduced life-threatening, major or critical-organ bleeding at 30 days, but non-inferiority for the cardiovascular safety composite was not established compared with placebo.HR 0.7695% CI 0.67-0.87Read →
- 2018MANAGECardiology · Cardioprotection · Antithrombotic therapyIn 1,754 patients with myocardial injury after non-cardiac surgery, dabigatran 110 mg twice daily reduced major vascular complications without a significant increase in major bleeding compared with placebo.HR 0.7295% CI 0.55-0.93Read →
- 2014POISE-2 CoreCardiology · Cardioprotection · Aspirin and clonidineIn 10,010 patients at risk of vascular complications undergoing non-cardiac surgery, neither low-dose aspirin nor clonidine started just before surgery reduced death or non-fatal myocardial infarction at 30 days; aspirin increased major bleeding and clonidine increased hypotension, compared with placebo.Read →
Preoperative revascularisation1
- 2004CARPCardiology · Cardioprotection · Preoperative revascularisationIn 510 patients with stable coronary artery disease scheduled for elective major vascular surgery, prophylactic coronary revascularisation before surgery did not reduce long-term all-cause mortality or postoperative myocardial infarction compared with no preoperative revascularisation.RR 0.9895% CI 0.70-1.37Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2012VISION
The cohort that established postoperative troponin elevation as an independent predictor of death — the origin of the MINS concept.
- 2009DECREASE family
Withdrawn after scientific misconduct; its retraction is why perioperative beta-blocker evidence rests on POISE alone.
- 2012IABP-SHOCK II
Intra-aortic balloon pump in cardiogenic shock — cited for perioperative haemodynamic support.
- 2015BRIDGE
Bridging anticoagulation before surgery in atrial fibrillation was unnecessary and caused bleeding.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.